Charles River Laboratories
568 hedge funds and large institutions have $12.9B invested in Charles River Laboratories in 2026 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 195 increasing their positions, 202 reducing their positions, and 62 closing their positions.
86% more call options, than puts
Call options by funds: $59M | Put options by funds: $31.7M
30% more capital invested
Capital invested by funds: $9.86B → $12.9B (+$2.99B)
26% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 62
1.79% more ownership
Funds ownership: 116.07% → 117.86% (+1.8%)
1% more funds holding
Funds holding: 560 → 568 (+8)
3% less repeat investments, than reductions
Existing positions increased: 195 | Existing positions reduced: 202
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$140M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$105M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$67.7M |
| 4 |
Citigroup
New York
|
+$41.8M |
| 5 |
Goldman Sachs
New York
|
+$40.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$106M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$81.6M |
| 3 |
Millennium Management
New York
|
-$79.7M |
| 4 |
Amundi
Paris,
France
|
-$64.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$60.7M |
CRL Hedge Fund Activity: Q2 2026 in Review
568 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q2 2026, worth a combined $12.9B — up 30% from $9.86B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new CRL positions and 62 closed out — a net gain of 16 holders — while 195 added to existing stakes and 202 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $140M. The largest seller was Mackenzie Financial, cutting an estimated $106M.
- 568 institutional investors held Charles River Laboratories (CRL) as of Q2 2026, up from 560 in Q1 2026.
- Funds reported $12.9B of Charles River Laboratories stock for Q2 2026, up 30% quarter-over-quarter.
- 78 funds opened new Charles River Laboratories positions in Q2 2026 and 62 closed out, a net change of +16 holders.
- The largest Charles River Laboratories buyer in Q2 2026 was Fidelity Investments, an estimated $140M added.
- The largest Charles River Laboratories seller in Q2 2026 was Mackenzie Financial, an estimated $106M sold.
Based on aggregated 13F filings for Q2 2026.